Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | JAK2 | O60674 | 2/20 | 0.41 |
| ▸ | JAK3 | P52333 | 2/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | TMPRSS2 | O15393 | 2/20 | 0.39 |
| ▸ | MAP3K5 | Q99683 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3727502 | 0.85 | ESR2 (0.51) | ESR2FFAR1NPC1RAB9AJAK2 | |
| SCHEMBL3727140 | 0.85 | LMNA (0.49) | ESR2NPC1RAB9ANR1H2MAP3K5 | |
| SCHEMBL3728485 | 0.83 | ESR2 (0.47) | ESR2FFAR1NPC1RAB9ANAMPT | |
| SCHEMBL3729629 | 0.81 | ESR2 (0.47) | ESR2NPC1RAB9AJAK2JAK3 | |
| SCHEMBL4554891 | 0.79 | FFAR1 (0.44) | FFAR1 | |
| SCHEMBL3732043 | 0.78 | LMNA (0.48) | ESR2NR1H2 | |
| SCHEMBL3729473 | 0.78 | ESR2 (0.51) | ESR2NPC1RAB9ANR1H2MAP3K5 | |
| SCHEMBL3741798 | 0.78 | ESR2 (0.47) | ESR2NPC1RAB9ANR1H2 | |
| SCHEMBL3728161 | 0.78 | ESR2 (0.47) | ESR2NPC1RAB9ANR1H2MAP3K5 | |
| Hydrochloric Acid SCHEMBL3725783 | 0.78 | FFAR1 (0.45) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120669-A1 | THIADIAZOLE DERIVATIVES, INHIBITORS OF STEAROYL-COA DESATURASE | BOUILLOT ANNE MARIE JEANNE | 2010-05-13 | — | — | US | disclosed |
| US-20100120669-A1 | THIADIAZOLE DERIVATIVES, INHIBITORS OF STEAROYL-COA DESATURASE | BOUILLOT ANNE MARIE JEANNE | 2010-05-13 | — | — | US | disclosed |
| US-20100120669-A1 | THIADIAZOLE DERIVATIVES, INHIBITORS OF STEAROYL-COA DESATURASE | BOUILLOT ANNE MARIE JEANNE | 2010-05-13 | — | — | US | disclosed |
| EP-2125799-A1 | THIADIAZOLE DERIVATIVES, INHIBITORS OF STEAROYL-COA DESATURASE | Smithkline Beecham Corporation (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008104524-A1 | THIADIAZOLE DERIVATIVES, INHIBITORS OF STEAROYL-COA DESATURASE | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008104524-A1 | THIADIAZOLE DERIVATIVES, INHIBITORS OF STEAROYL-COA DESATURASE | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120669-A1 | THIADIAZOLE DERIVATIVES, INHIBITORS OF STEAROYL-COA DESATURASE | SCD, SCD5, FADS2 | ESR2 3678/4885FFAR1 518/4885NPC1 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.